Amiral Gestion Buys New Shares in Edwards Lifesciences Co. (NYSE:EW)

Amiral Gestion acquired a new stake in Edwards Lifesciences Co. (NYSE:EW - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 91,292 shares of the medical research company's stock, valued at approximately $6,757,000. Edwards Lifesciences comprises about 4.3% of Amiral Gestion's portfolio, making the stock its 9th largest position.

Other large investors also recently added to or reduced their stakes in the company. Crowley Wealth Management Inc. purchased a new position in Edwards Lifesciences in the fourth quarter valued at $26,000. Vega Investment Solutions purchased a new position in Edwards Lifesciences in the fourth quarter valued at $27,000. Millstone Evans Group LLC purchased a new position in Edwards Lifesciences in the fourth quarter valued at $29,000. Migdal Insurance & Financial Holdings Ltd. purchased a new position in Edwards Lifesciences in the fourth quarter valued at $30,000. Finally, Catalyst Capital Advisors LLC purchased a new position in Edwards Lifesciences in the fourth quarter valued at $54,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Price Performance

NYSE EW traded up $0.51 during trading hours on Thursday, reaching $77.17. 1,274,308 shares of the company's stock were exchanged, compared to its average volume of 5,144,403. The stock has a market cap of $45.27 billion, a PE ratio of 11.07, a price-to-earnings-growth ratio of 4.82 and a beta of 1.12. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $95.25. The firm has a fifty day moving average of $73.09 and a 200-day moving average of $72.25. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share for the quarter, beating analysts' consensus estimates of $0.60 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. The company had revenue of $1.41 billion for the quarter, compared to the consensus estimate of $1.40 billion. During the same quarter in the prior year, the business posted $0.66 EPS. The firm's quarterly revenue was up 6.2% on a year-over-year basis. On average, equities research analysts predict that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Analyst Ratings Changes

EW has been the topic of several research reports. Citigroup reaffirmed a "buy" rating and set a $95.00 price objective (up previously from $84.00) on shares of Edwards Lifesciences in a report on Thursday, May 22nd. Piper Sandler raised their price objective on Edwards Lifesciences from $80.00 to $83.00 and gave the stock an "overweight" rating in a report on Tuesday, May 13th. Wall Street Zen lowered Edwards Lifesciences from a "buy" rating to a "hold" rating in a report on Friday, May 16th. Barclays raised their price objective on Edwards Lifesciences from $88.00 to $90.00 and gave the stock an "overweight" rating in a report on Thursday, February 13th. Finally, Robert W. Baird raised their price target on Edwards Lifesciences from $72.00 to $75.00 and gave the stock a "neutral" rating in a report on Thursday, April 24th. One research analyst has rated the stock with a sell rating, thirteen have given a hold rating and eleven have issued a buy rating to the stock. Based on data from MarketBeat.com, Edwards Lifesciences currently has an average rating of "Hold" and a consensus target price of $80.20.

Insider Buying and Selling

In related news, VP Daniel J. Lippis sold 400 shares of the firm's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $69.48, for a total transaction of $27,792.00. Following the sale, the vice president now owns 22,588 shares of the company's stock, valued at approximately $1,569,414.24. This trade represents a 1.74% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, VP Donald E. Bobo, Jr. sold 9,500 shares of Edwards Lifesciences stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $67.96, for a total value of $645,620.00. Following the completion of the sale, the vice president now directly owns 46,936 shares in the company, valued at $3,189,770.56. This represents a 16.83% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 67,692 shares of company stock valued at $4,822,074. 0.34% of the stock is owned by company insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.